At the end of the latest market close, Akebia Therapeutics Inc. (AKBA) was valued at $2.95. In that particular session, Stock kicked-off at the price of $2.96 while reaching the peak value of $3.03 and lowest value recorded on the day was $2.84. The stock current value is $2.87.
Recently in News on December 9, 2020, AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth. Virtual Panel of Nephrology Care Professionals to Share Insights and Experiences Managing Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Akebia Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $13.71 on 07/07/20, with the lowest value was $2.09 for the same time period, recorded on 10/30/20.
Akebia Therapeutics Inc. (AKBA) full year performance was -54.80%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Akebia Therapeutics Inc. shares are logging -79.07% during the 52-week period from high price, and 37.32% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.09 and $13.71.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 5752625 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Akebia Therapeutics Inc. (AKBA) recorded performance in the market was -54.59%, having the revenues showcasing 6.30% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 426.40M, as it employees total of 360 workers.
Specialists analysis on Akebia Therapeutics Inc. (AKBA)
During the last month, 0 analysts gave the Akebia Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.22, with a change in the price was noted -9.38. In a similar fashion, Akebia Therapeutics Inc. posted a movement of -76.57% for the period of last 100 days, recording 6,323,511 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AKBA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.24.
Trends and Technical analysis: Akebia Therapeutics Inc. (AKBA)
Raw Stochastic average of Akebia Therapeutics Inc. in the period of last 50 days is set at 37.32%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 42.35%. In the last 20 days, the company’s Stochastic %K was 43.18% and its Stochastic %D was recorded 48.55%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -54.59%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -76.34%, alongside a downfall of -54.80% for the period of the last 12 months. The shares increased approximately by -6.82% in the 7-day charts and went down by 11.67% in the period of the last 30 days. Common stock shares were driven by 6.30% during last recorded quarter.